Watch ADMA. Know when insiders buy.
One email the day a filing lands. Free.
ADMA
ADMA BIOLOGICS, INC.
9.62
+0.04 +0.42%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
42
WATCH · shorts 42
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.2BP/E 13.7DIV YIELD —FCF YIELD 5.41%REV TTM $512.3M +8.0%NET INCOME $169M −19.1%NET DEBT $60.6M52W 7.60 – 20.38SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $124.4M | +2.0% | 69.4% | $52.4M | $37.8M | +10.5% | 0.16 | $29.5M | $2.3M | $27.3M | Aug 5 |
| Q1 2026 · Mar 31 | $114.5M | −0.3% | 70.5% | $58.3M | $45.3M | +68.5% | 0.19 | $58.2M | $2.5M | $55.7M | Aug 5 |
| Q4 2025 · Dec 31derived | $139.2M | +18.4% | 63.8% | $62.8M | $49.4M | −55.9% | 0.20 | $35.6M | $1.1M | $34.6M | Feb 25 |
| Q3 2025 · Sep 30 | $134.2M | +12.0% | 56.3% | $51M | $36.4M | +1.4% | 0.15 | $13.3M | $14.4M | −$1.1M | Nov 5 |
| Q2 2025 · Jun 30 | $122M | +13.8% | 55.1% | $42.8M | $34.2M | +6.7% | 0.14 | $21.1M | $2.4M | $18.7M | Aug 5 |
| Q1 2025 · Mar 31 | $114.8M | +40.2% | 53.2% | $34.9M | $26.9M | +51.1% | 0.11 | −$19.7M | $4.7M | −$24.4M | Aug 5 |
| Q4 2024 · Dec 31derived | $117.5M | +59.1% | 53.9% | $38.3M | $111.9M | — | 0.46 | $50.2M | $2.8M | $47.5M | Feb 25 |
| Q3 2024 · Sep 30 | $119.8M | +78.1% | 49.8% | $39.6M | $35.9M | +1300.0% | 0.15 | $25M | $1.1M | $24M | Nov 5 |
| Q2 2024 · Jun 30 | $107.2M | — | 53.6% | $39.2M | $32.1M | — | 0.13 | $45.6M | $2.1M | $43.6M | Nov 5 |
| Q1 2024 · Mar 31 | $81.9M | — | 47.8% | $21.8M | $17.8M | — | 0.08 | −$2.2M | $2.3M | −$4.6M | Nov 5 |
| Q4 2023 · Dec 31derived | $73.9M | — | 42.1% | $14.2M | −$17.6M | — | -0.08 | $17.6M | $1.2M | $16.4M | Feb 25 |
| Q3 2023 · Sep 30 | $67.3M | — | 36.6% | $8.7M | $2.6M | — | 0.01 | $12M | $757K | $11.2M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $510.2M | 57.4% | $191.4M | $146.9M | 28.8% | 0.60 | $50.4M | $22.6M | $27.8M | $31.9M | — |
| FY2024 · to Dec 31 | $426.5M | 51.5% | $139M | $197.7M | 46.4% | 0.81 | $118.7M | $8.2M | $110.4M | $0 | — |
| FY2023 · to Dec 31 | $258.2M | 34.4% | $21.6M | −$28.2M | -10.9% | -0.13 | $8.8M | $4.8M | $4M | $0 | — |
| FY2022 · to Dec 31 | $154.1M | 22.9% | −$39.4M | −$65.9M | -42.8% | -0.33 | −$59.5M | $13.9M | −$73.4M | — | — |
| FY2021 · to Dec 31 | $80.9M | 1.4% | −$58.4M | −$71.6M | -88.5% | -0.51 | −$112.4M | $13.5M | −$125.9M | — | — |
| FY2020 · to Dec 31 | $42.2M | -45.2% | −$64.9M | −$75.7M | -179.4% | -0.88 | −$102M | $12.7M | −$114.7M | — | — |
Every number comes from ADMA BIOLOGICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.